Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.
A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Latest From Neena Brizmohun
The Therapeutic Goods Administration’s provisional approval for Gilead Sciences’ drug comes with a number of post-marketing obligations for the company.
Some reimbursement agencies in Europe have been misinterpreting Translarna’s label and stopping access to the drug for boys with Duchenne muscular dystrophy who have been taking it but whose disease has progressed, PTC says.
A European pilot project that lets drug companies developing innovative products receive scientific advice from two EU member states at the same time is proving its worth during the pandemic.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, including Celgene's Reblozyl for treating transfusion-dependent anemia in adult patients with myelodysplastic syndromes or beta thalassemia. The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
European Medicines Agency has made a choice of a nominee to be its next executive director.